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Optical imaging-based diagnostics identify malignancies based on molecular changes instead of
morphological criteria in a non-invasive, irradiation free process. The aim of this study was to improve
imaging efﬁciency by the development of a new Cholecystokinin-2-receptor targeted ﬂuorescent peptide
that matches the clinical needs regarding biodistribution and pharmacokinetics while displaying supe-
rior target speciﬁcity. Furthermore we performed multifactorial imaging of Cholecystokinin-2-receptor
and tumor metabolism, since simultaneous targeting of various tumor biomarkers could intensely in-
crease tumor identiﬁcation and characterization. Afﬁnity and speciﬁcity of the ﬂuorescent Cholecysto-
kinin-2-receptor targeted minigastrin (dQ-MG-754) were tested in vitro. We conducted in vivo imaging of
the dQ-MG-754 probe alone and in a multifactorial approach with a GLUT-1 targeted probe (IR800 2-DG)
on subcutaneous xenograft bearing athymic nude mice up to 24 h after intravenous injection (n ¼ 5/
group), followed by ex vivo biodistribution analysis and histological examination. We found speciﬁc, high
afﬁnity binding (Kd ¼ 1.77 nM  0.6 nM) of dQ-MG-754 to Cholecystokinin-2-receptor expressing cells
and xenografts as well as favorable pharmacokinetics for ﬂuorescence-guided endoscopy. We success-
fully performed multifactorial imaging for the simultaneous detection of the Cholecystokinin-2-receptor
and GLUT-1 targeted probe. Prominent differences in uptake patterns of the two contrast agents could be
detected. The results were validated by histological examinations. The multifactorial imaging approach
presented in this study could facilitate cancer detection in diagnostic imaging and intraoperative and
endoscopic applications. Especially the dQ-MG-754 probe bears great potential for translation to clinical
endoscopy imaging, because it combines speciﬁc high afﬁnity binding with renal elimination and a
favorable biodistribution.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Optical imaging is rapidly advancing toward clinical application
for early cancer detection and intraoperative imaging [1]. Beyond
the recognition of only visible morphological changes, it enables
the non-invasive detection of molecular changes in malignant cells.
In this context, ﬂuorescent probes have been developed for a wide
range of tumor speciﬁc targets, mostly addressing only one speciﬁcax: þ49 3641 9325922.
ax: þ49 3641 9325922.
e (S. Kossatz), ingrid.hilger@
-ND license.marker in each approach. Considering that pathobiological mech-
anisms are very complex, the visualization of several tumor
markers at a time could fundamentally improve tumor detection
and characterization. The implementation of such multifactorial
approaches, for example in ﬂuorescence-guided endoscopy, could
foster early identiﬁcation of malignant cells [2] and prognosis by
assessment of their developmental stage.
Particularly in relation to the identiﬁcation of colon cancers, the
second leading cause of death in men and women in developed
countries [3,4], small or ﬂat lesions are often missed in conven-
tional endoscopic screening [5]. In these cancers the cholecysto-
kinin-2-receptor (CCK2R), is one of the receptors which is
overexpressed early in the transition from adenoma-carcinoma,
allowing for early discovery of malignant lesions [6]. The receptor
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invasiveness of various tumor types [7e10] by CCK2R dependent
activation of several tumorigenic pathways [11e14]. The expression
of the receptor in normal tissue is primarily located in the central
nervous system and in the stomach, whereas it has been reported
that in the normal colon the CCK2R is not expressed [6].
In 1999, a short 7 amino acid sequence called “minigastrin” has
been selected from a large screening for CCK2R binding peptides
[15]. Since then several chelate basedminigastrin analogswith high
target afﬁnity, fast kinetics and renal elimination have been
developed to improve tumor targeting properties [16,17].
Replacement of the radioactive moiety with a near infrared ﬂuo-
rophore makes these substances available for ﬂuorescence endos-
copy or intraoperative imaging [18]. However, improved
ﬂuorescent minigastrins with suitable pharmacokinetics and su-
perior target afﬁnity remain to be identiﬁed [19].
In terms of multifactorial imaging, an important functional
change in cancer development is acceleration of glucose meta-
bolism [20]. The observations of prevalent GLUT-1 overexpression
in tumors and correlations to poor prognosis and chemotherapy
resistance are already being widely exploited in 18F-FDG nuclear
imaging of tumors [21]. Translation of GLUT-1 imaging to optical
imaging led to the development of a commercially available 2-
deoxy-D-glucose (2-DG), where the radioligand was replaced by
the near infrared dye IRDye 800CW [22]. So far, reports on the
reliability of the probe have been somewhat contradictory.
Whereas some research reports proposed a speciﬁc binding
mechanism [22,23], another research proposed an EPR effect
dependent accumulation [24].
Here, we explored the feasibility of multifactorial NIR optical
imaging with a CCK2R targeted peptide and a ﬂuorescent 2-DG
probe. We aimed at synthesizing a CCK2R targeted probe by link-
ing a NIRF dye via a hydrophilic linker to a high-afﬁnity peptide to
obtain pharmacokinetic properties ﬁtted to prospective clinical
endoscopic imaging. Our hypothesis was that probe properties
could be selectively modulated to increase afﬁnity, speciﬁcity, and
renal elimination. To show the feasibility of the multispectral
approach, we explored and characterized differences in uptake
patterns of the two contrast agents in subcutaneous xenografts
in vivo. We propose that the approach described here could foster
the development of multifactorial approaches in optical imaging.
2. Material and methods
2.1. Cell lines
A431/CCK2R and A431/WT, human epidermoid carcinoma cells were a gift from
Dr. Luigi Aloj (Department of Nuclear Medicine, Instituto Nazionale Tumouri, Fon-
dazione “G. Pascale”, Naples, Italy). The cells were stably transfected with either the
CCK2-Receptor (A431/CCK2R) or with empty vector (A431/WT) [25]. Authenticity of
the cells was conﬁrmed by DSMZ (Deutsche Sammlung für Mikroorganismen und
Zellkulturen) in 2012. HT-29 and LS174T colorectal adenocarcinoma cell lines were
obtained from DSMZ and CLS. All cell lines were grown in a monolayer culture at
37 C in a 5% CO2 humidiﬁed atmosphere. They were maintained in D-MEMmedium
with 10% (v/v) FBS (both Gibco (Invitrogen)) and passaged regularly at 70e80%
conﬂuency.
2.2. Animals
Female athymic nude mice (Hsd:Athymic Nude-Foxn1nu nu/nu; Harlan Labo-
ratories) were housed under standard conditions with water and food ad libitum.
Mice were maintained under a low-pheophorbide diet (C 1039; Altromin) to reduce
tissue autoﬂuorescence. All procedures were approved by the regional animal
committee and were in accordance with international guidelines on the ethical use
of animals. Throughout all procedures, animals were anesthetized with 2% iso-
ﬂurane. To implement subcutaneous xenografts, 5  105 cells (A431/CCK2R and
A431/WT) or 2  106 cell (HT-29 and LS174T) were dispensed in Matrigel (BD
Biosciences) and injected into right (A431/CCK2R cells) and left (A431/WT cells)
ﬂank or the middle of the back (HT-29 and LS174T) of 8e12 weeks old animals 10e
15 days before in vivo imaging.2.3. Target expression in A431/CCK2R und A431/WT cells
RNA isolation from 5  106 cells with TRIzol (Invitrogen) was performed ac-
cording to standard protocol [26]. After cDNA synthesis with the QuantiTect RT Kit
(Qiagen), SYBR green qRT-PCR was performed on a RotorGene Q (Qiagen). Re-
actions consisted of RotorGene SYBR Green Mastermix (Qiagen), forward/reverse
Primer (see Fig. S1) DEPC water and cDNA. Samples were denaturized at 95 C and
ampliﬁcation was carried out over 40 cycles of 5 s 95 C and 10 s 60 C. CCK2R gene
expression was relatively quantiﬁed using the DDCt method.
2.4. Synthesis of CCK2R targeted probe “dQ-MG-754” with improved
pharmacokinetics
We designed a NIRF peptide probe for CCK2R imaging. The hemicyanine ﬂuo-
rescent dye DY-754 (Dyomics) was used as signaling moiety of the probe construct.
This dyewas selected out of six different hemicyanine NIR dyes (DY-676, DY-677, DY-
678, DY-751, DY-752 and DY-754) due to its low nonspeciﬁc binding to the gastro-
intestinal tract and renal elimination pattern (see Supplementary Figs. 1 and 2).
Then, a N-Hydroxysuccinimide-ester of DY-754 was N-terminally coupled to the
minigastrin peptide analog with the sequence H2N-(DGln)6-Ala-Tyr-Gly-Trp-Met-
Asp-Phe-amid [27]. The probe construct was named “dQ-MG-754”. Peptide syn-
thesis, dye coupling and HPLC puriﬁcation were carried out by Peptide Specialty
Laboratories (PSL).
2.5. In vitro dQ-MG-754 probe uptake into A431/CCK2R and A431/WT cells
For determination of probe uptake, cells were seeded into chamber slides and
incubatedwith 5 nM dQ-MG-754 in culturemedium at 4 C and 37 C for 30min. Cell
membranes were stained with Alexa-555 conjugated wheat germ agglutinin (WGA-
555; Invitrogen) and subsequently ﬁxated with 4% paraformaldehyde (Roth). Cells
were mounted with PermaFluor mounting medium (ThermoFischer) containing
Hoechst 33258 DNA stain (Applichem). Using a laser scanning microscope (LSM 510,
Zeiss), cell nuclei were visualized with a 405 nm laser diode and a 420e480 nm
bandpass ﬁlter. For cell membranes, a 543 nm HeNe laser and a 550e615 nm
bandpass ﬁlter were applied, ﬂuorescence of dQ-MG-754 was excited with a 633
Argon Laser and emission was detected with a 650 nm longpass ﬁlter. Binding
speciﬁcity was controlled by incubation of cells with either the probe together with
10-fold excess unlabeled peptide or an equimolar concentration of DY-754.
Furthermore interactions of dQ-MG-754 probe with tumor (A431/CCK2R and
A431/WT), endothelial (HMEC-1) and kidney cells (HEK293) were investigated by
the means of real time impedance measurement (xCELLigence, Roche). Therefore,
cells were incubatedwith 50 mM probe over a period of 96 h. Change of impedance by
proliferation activities of cells was measured as “Cell Index” [28] and normalized to
untreated cells.
2.6. Fluorescence based determination of binding afﬁnity
To obtain a saturation binding curve, 2  106 A431/CCK2R cells were incubated
with serial dilutions from 0.1 to 50 nM of dQ-MG-754 for 5 min at room temperature
to measure total probe binding. To determine nonspeciﬁc binding, the same probe
concentrations were used in presence of 100-fold excess unlabeled peptide (D-Leu-
minigastrin, Bachem). After centrifugation cell pellets were immediately imaged
with the small animal imaging systemMaestro (CRi). A region of interest (ROI) was
assigned to each cell pellet in order to measure ﬂuorescence intensity semi-
quantitatively. Fluorescence intensities were described as average signal (scaled
counts/s). This value represents count levels after scaling for exposure time, camera
gain, binning and bit depth, hencemeasurements are comparable among each other.
Binding curves and dissociation constants were determined using Graphpad Prism
5. Speciﬁc binding was assessed by subtracting nonspeciﬁc binding signal from total
binding signal.
Determination of the Ki value was carried out by preincubating cells with
increasing concentrations of unlabeled peptide from 0.1 to 2000 nM directly before
adding a ﬁxed probe concentration of 2 nM to all samples. Thereafter, the same
procedure as described above was followed.
2.7. In vivo imaging of CCK2R expression and elevated rate of glycolysis
When subcutaneous xenografts reached a diameter of 5e7 mm, in vivo imaging
was initiated by tail vain injection of the respective contrast agent. For solitary im-
aging of dQ-MG-754, we injected 108 nmol/kg. To control signal speciﬁcity, animals
received probe together with a 10-fold excess of unlabeled D-Leu-minigastrin or the
native ﬂuorophore (108 nmol/kg of DY-754). For multifactorial imaging of CCK2R
expression and elevated rate of glycolysis we injected 108 nmol/kg dQ-MG-754 and
608 nmol/kg IRDye 800CW 2-DG (short: IR800 2-DG; LI-COR) simultaneously.
At deﬁned time points after injection, animals were imaged in the Maestro
using ﬁlters for excitation (670e710 nm) and emission (longpass > 750 nm).
Semiquantitative analysis of ﬂuorescence intensities was carried out as described
above. Each contrast agent was analyzed separately for its distinct ﬂuorescence
spectrum after subtraction of autoﬂuorescence. A tumor to background ratio (TBR)
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a deﬁned ROI in the tumor area by a ROI of normal tissue between the animal’s ears.
A TBR of 3 was considered to be a contrast suitable for unequivocal tumor
detection.
2.8. Ex vivo determination of improved pharmacokinetic properties of dQ-MG-754
Animals were sacriﬁced 8 h after injection and ﬂuorescence intensities of the
organs, GI tract A431/CCK2R and A431/WT tumors were determined with the
Maestro. We used the same protocol as described above to measure and compare
organ ﬂuorescence of animals injected with probe, block, DY-754 and control ani-
mals (nothing injected). Excised tumors were processed for histological analysis.
2.9. Analysis of probe distribution in tumor tissue ex vivo
To determine the distribution and localization of dQ-MG-754 and IR800 2-DG
within the tumor tissue, we recorded macroscopic scans of 30 mm tumor cry-
osections (Odyssey, LI-COR). Autoﬂuorescencewas determined at 700 nm and probe
ﬂuorescence at 800 nm.
2.10. Determination of xenograft vascularization
We used the Chalkley counting method to estimate tumor vascularity as rec-
ommended in an international consensus [29]. Detailed description of the method
can be found elsewhere [30,31]. Vessels were stained with CD31. Brieﬂy, ﬁxed cry-
osections were blocked with Biotin Blocking System (Dako), according to the
manufacturers’ recommendations. Primary antibody (rat anti mouse-CD31,
MEC13.3, 0.625 mg/mL, BD Biosciences) incubation for 1 h was followed by sec-
ondary antibody (biotinylated IgG2a 0.25mg/mL, BD Biosciences) for 45min, both at
room temperature. The Dako REAL Detection System (Dako) was used for
streptavidin-biotin detection. Between these steps slides were washed with TBS-T
buffer. Cell nuclei were counterstained with Mayer’s hematoxylin (Fluka/Sigmae
Aldrich) and mounted with gelatine (SERVA Electrophoresis).
2.11. Immunohistochemical validation of target expression in xenografts (GLUT-1,
CCK2R)
For staining of GLUT-1 receptor, parafﬁn sections were deparafﬁnized, followed
by antigen demasking at 98 C for 10 min in EDTA buffer pH 9.0. Slides were blockedDY-754-dGln-(dGln)5
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Fig. 1. CCK2R targeted probe design and target expression. (A) Chemical structure of dQ-M
Spectroscopic features of the probe, (C) Photophysical and spectroscopic probe properties are
Photoluminescence Quantum Yield Measurement System at 700 nm. Photostability was dewith the avidin/biotin blocking system (Dako) and 5% goat serum. Thereafter pri-
mary antibody (polyclonal rabbit anti-human GLUT1, NB110-39112, 4 mg/ml) was
added for 1 h at room temperature. Secondary antibody incubation and
streptavidin-biotin detection were carried out with the Dako Kit 5005 (Dako) ac-
cording to the manufacturers’ recommendations. Between all steps slides were
washed with TBS-T buffer.
For immunodetection of CCK2R expression, formalin-ﬁxed parafﬁn-embedded
tissue sections were dewaxed and placed in a microwave (10 min, 600W) to recover
antigens before incubation with the CCK2R antibody (1:300; PAB6797, Abnova),
followed by secondary biotinylated antibody (Vector Laboratories). Peroxidase
conjugated streptavidin was used with 3,30-diaminobenzidine tetrahydrochloride
(DAB, SigmaeAldrich) as chromogen for detection. Cell nuclei were counterstained
with Mayer’s hematoxylin (Fluka/SigmaeAldrich) and mounted with gelatine
(SERVA Electrophoresis).
2.12. Statistics
To determine the level of signiﬁcance, student’s t-test was used, if normality and
equal variance tests were passed. Otherwise Mann-Whitney-Rank Sum Test was
applied. All experiments were done at least in triplicate and experimental in vivo
groups consisted of 5 or more animals.3. Results
3.1. Features of the probes and target cells
The CCK2R targeted probe dQ-MG-754 (Fig. 1A) featured near-
infrared excitation and emission spectra (Fig. 1B), while exhibit-
ing low molecular weight of M ¼ 2604 g/mol and a strongly
negative log P value, which is an indicator of high hydrophilicity.
Basic spectroscopic and photophysical parameters are listed in
Fig. 1C.
The dye component of the probe, DY-754, was chosen from
preliminary experiments, where we comparatively evaluated two
groups of three NIR dyes (Suppl. Fig. S1AþB). The dyes with four-Ala-Tyr-Trp-Met-Asp-Phe-amid
O
O O O O O
O
O
H
H
H
H
H
S
N N
N
N N N N
Probe characteristics
Excitation
Quantum
Yield
Photo-
stability
13.1% 31.1 min
Fluorescence
lifetime
720 ps
MW 2604 g/mol Log (P) -2.949
Emission748 nm 774 nm
G-754, composed of a hemicyanine ﬂuorescent dye and a dQ6-minigastrin peptide, (B)
presented in the table. Quantum yield was measured with a Hamamatsu C9920-2 Total
termined in water during white light exposure.
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speciﬁc binding to non-cancerous tissue of the gastrointestinal
tract compared to the dyes with two or three sulfonate groups
(Suppl. Fig. S1CþD). Furthermore, we demonstrated that DY-754
was the only dye to show almost exclusive clearance through the
kidneys in mice in vivo (Suppl. Fig. S2AþB). DY-751 and DY-752
were partly or completely subject to hepatobiliary elimination,
with resulting intense ﬂuorescence in the intestine (Suppl.
Fig. S2C). qPCR conﬁrmed that only the transfected A431/CCK2R
cells expressed high mRNA levels of CCK2R (Suppl. Fig. S3).
3.2. Probe binding to CCK2R expressing cells
Microscopic analysis showed strong binding of the dQ-MG-754
probe to A431/CCK2R cells. Internalization was observed at 37 C,
but not at 4 C (Fig. 2A). The probe bound A431/CCK2R cells but not
A431/WTcells (Fig. 2B-I and B-II). Bindingwas strongly inhibited by
preincubation with an excess of unlabeled peptide, which blocks
the speciﬁc binding sites (Fig. 2B-III). The dye DY-754 alone dis-
played no binding to both tested cell lines (Fig. 2B-IV). Furthermore
we could show that binding of dQ-MG-754 also occurred to HT-29Fig. 2. In vitro characterization reveals a speciﬁc cell uptake of the dQ-MG-754 probe an
membrane (green) at 4 C and close to the nucleus (blue) at 37 C. B) dQ-MG-754 probe up
incubation at 37 C. Incubation with excess unlabeled D-Leu-minigastrin (III) and free DY-754
33258, Green: cell membranes stain WGA-Alexa 555, Red: dQ-MG-754. C) Saturation bind
1.77 nM  0.6 nM. The graph insert shows a Ki value of 7.6 nM  0.04 nM. D) Incubation of tum
cell viability. A transient increase in proliferation was observed in A431/CCK2R cells. The
n ¼ 3  SEM.and LS174T colorectal adenocarcinoma cells, but not to A431/WT
and HMEC-1 cells (Suppl. Fig. 5AeB).
The saturation binding assay demonstrated high binding afﬁnity
to receptor expressing cells, with a Kd value of 1.77 nM  0.6 nM
(Fig. 2C). The competitive displacement cell binding assay with
unlabeled D-Leu-minigastrin as competitor revealed a Ki value of
7.6 nM  0.04 nM (Fig. 2C). Incubation of tumor and non-tumor cell
lines with dQ-MG-754 showed no negative inﬂuence on cell
viability. A transient increase in proliferationwas observed in A431/
CCK2R cells (Fig. 2D).
3.3. In vivo imaging of CCK2R expressing tumors
After intravenous probe injection, we observed a fast, high
contrast and long lasting accumulation in tumors expressing CCK2R
(Fig. 3). A much weaker accumulation occurred in A431/WT xe-
nografts and background tissue. The tumor to background ratios
(TBR) in A431/CCK2R xenografts after probe application exhibited
values 3 from 2 h to 24 h after probe application (Fig. 3). Blocking
of speciﬁc binding sites by 10-fold excess of competing unlabeled
peptide reduced probe accumulation in A431/CCK2R tumors by 53%d cytotoxic harmlessness. A) dQ-MG-754 probe binding (red) was located at the cell
take occurs only into receptor expressing (I) and not in non-expressing cells (II) after
(IV) was carried out to control for speciﬁcity of probe uptake. Blue: DNA stain Hoechst
ing curve of dQ-MG-754 to A431/CCK2R cells reveals a dissociation constant (Kd) of
or and non-tumor cell lines with 50 mM dQ-MG-754 showed no negative inﬂuence on
cell index [28] is presented relative to untreated cells. All graphs display means of
Fig. 3. dQ-MG-754 probe accumulates speciﬁcally in A431/CCK2R xenografts. NIR ﬂuorescence reﬂectance images of CCK2R expression in an A431/CCK2R (right ﬂank) and A431/
WT (left ﬂank) xenograft model. The left panel displays representative intensity scaled ﬂuorescence images for each experimental group at indicated time points after probe
injection. “Tumor to background ratios“ (TBRs) in the right panel represent relative tumor uptake of each group. Error bars indicate SEM (n ¼ 5; except dQ-MG-754 group 0e8 h:
n ¼ 12). Images were acquired with the Maestro.
Fig. 4. Average signal intensity of tumors correlates with angiogenesis. Vessel density
as determined by Chalkley count shows a tendency towards higher vascularization in
A431/CCK2R xenografts compared to A431/WT xenografts (p ¼ 0.057). Chalkley count
units are related to the mean number of points on a Chalkley 25-point eyepiece
graticule that overlap with vessels in vascular hotspots. Detailed description of the
method can be found in the literature [29,30].
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Analysis of probe kinetics showed that the ﬂuorescence signal
peaked directly after application with subsequent gradual washout
(Suppl. Fig. S4). We observed a signiﬁcantly reduced washout of
dQ-MG-754 probe in A431/CCK2R tumors compared to the blocked
ones (p  0.05) between 2 and 8 h p.i.. In contrast, the washout in
A431/WT tumors could not be delayed.
To secure that the xenograft models featured comparable drug
delivery characteristics we quantiﬁed tumor vascularization. We
found both xenograft models well vascularized, however the A431/
CCK2R tumors (8.04  1.77) presented an elevated chalkley count
compared to A431/WT tumors (6.9  1.06) (Fig. 4). Therefore drug
delivery is essentially comparable, but the differences in vascular-
ization could account for slightly higher unspeciﬁc accumulation in
the receptor expressing tumors.
We could corroborate a favorable probe biodistribution, in terms
of prospective intraoperative and endoscopic imaging, by exami-
nation of organ ﬂuorescence 8 h p.i. (Fig. 5A). We observed high
kidney ﬂuorescence and strong ﬂuorescence signal which corre-
latedwith the anatomical localization of the bladder. These ﬁndings
veriﬁed that the probe was cleared through the kidneys and
excreted via the bladder in a manner comparable to DY-754
(Fig. 5B). Only a small proportion was processed through the
liver, resulting in low liver ﬂuorescence. Other organs did not
exhibit notable ﬂuorescence signals. Interestingly, there were no
detectable ﬂuorescence signals in the gastrointestinal tract, which
could potentially disturb endoscopic imaging.
The dQ-MG-754 probe was also able to image physiological
CCK2R expression in xenografts derived from colorectal adenocar-
cinoma cells HT-29 and LS174T. Probe accumulation in tumor tissuewas fast and high tumor to background contrasts were reached
between 1 and 24 h p.i. (Suppl. Fig. 5C). For HT-29 tumors, 24 h p.i.
we found a TBR of 4.8 0.4 and for LS174T the TBR was 3.8 0.4. To
determine the speciﬁcity of this uptake we performed a blocking
experiment as described above. Blocking experiments led to a 49%
lower TBR at 24 h p.i. in HT-29 tumors (2.4 0.5, p¼ 0.009) and to a
41% lower TBR in LS174T xenografts (2.2  0.1, p ¼ 0.02) (Suppl.
Fig. 5D).
Fig. 5. Biodistribution of dQ-MG-754 shows high tumor uptake and kidney retention. Biodistribution analysis 8 h p.i. revealed speciﬁc tumor uptake of dQ-MG-754 probe and high
kidney uptake. Other organs and the gastrointestinal tract showed very low probe uptake. Images represent organ distribution after administration of dQ-MG-754 probe (A-I), block
(probe and 10fold excess of unlabeled peptide) (A-II), and DY-754 (A-III). Renal elimination was displayed by ﬂuorescence in the bladder, which became visible directly after in-
jection of DY-754 and dQ-MG-754 probe and persisted through the whole imaging process (B). Images were acquired with the Maestro.
S. Kossatz et al. / Biomaterials 34 (2013) 5172e5180 51773.4. Multifactorial imaging of CCK2R expression and glycolysis
We were able to simultaneously detect the signals of both
applied contrast agents, the CCK2R targeted dQ-MG-754 probe and
IR800 2-DG to identify tumor metabolism in form of elevated
glycolysis. Tenacity of the applied method for discrimination of the
ﬂuorescence signatures from the two probes can be found in Suppl.
Fig. 6.
CCK2R expression was clearly identiﬁed by intense accumula-
tion in the A431/CCK2R xenografts 8 h post injection, with TBRs
comparable to single probe application. Likewise, a negligible
accumulation was observed in A431/WT tumors. In contrast, the
accumulation of IR800 2-DG was comparable in A431/CCK2R and
A431/WT tumors with slowly increasing TBRs that reached their
maximum at 24 h p.i. (Fig. 6A).
Looking at the individual tumors instead of mean values
revealed that IR800 2-DG reached a distinct accumulation in 60%
(6/10) of A431/CCK2R and in 60% (6/10) of A431/WT xenografts,
deﬁned by a TBR > 3 for IR800 2-DG (Fig. 6B). The other four xe-
nografts of each cell line would not have been detected as tumors
based on IR800 2-DG, because tumor ﬂuorescence was not partic-
ularly higher than background ﬂuorescence. Individual analysis of
dQ-MG-754 uptake, on the other hand, showed that 100% of A431/CCK2R xenografts had a TBR > 3 for dQ-MG-754 and 100% of A431/
WT xenografts had a TBR of <3 for dQ-MG-754 (Fig. 6B).
Furthermore, imaging showed differential intratumoral locali-
zation of each contrast agent (Fig. 6C).3.5. Probe and target distribution in tumors
Ex vivo organ ﬂuorescence as well as macroscopically scanned
cryosections of tumors showed differential accumulation of the
investigated contrast agents. The CCK2R targeted dQ-MG-754
probe displayed strong and homogeneously distributed ﬂuores-
cence signals in explanted xenografts and cryosections of A431/
CCK2R tumors, but very weak ﬂuorescence in A431/WT tumors
(Fig. 6D). Immunohistochemical validation of CCK2R expression
showed a corresponding staining in A431/CCK2R tumors which
was absent in A431/WT tumors.
Opposed to this, accumulation of IR800 2-DG was either
heterogenous with pronounced signals in the central necrotic and
perinecrotic tumor regions or very weak throughout the tumor, as
seen in ﬂuorescence analysis of explanted tumors and macroscopic
scans of tumor cryosections (Fig. 6E). Histological staining of GLUT-
1 receptor revealed a ubiquitous receptor expression in the vital
Fig. 6. Differential uptake pattern of dQ-MG-754 and IR800 2-DG probes 24 h after simultaneous administration. (A) CCK2R targeted dQ-MG-754 probe showed strong uptake only
into receptor expressing tumors. IR800 2-DG probe showed moderate, but similar uptake into A431/CCK2R and A431/WT tumors. Bars display means and SEM of n ¼ 5. (B) In-
dividual subject analysis revealed that dQ-MG-754 accumulated in all A431/CCK2R tumors (quadrants II and III) and in none of the A431/WT tumors (quadrants I and IV), whereas
the IR800 2-DG probe accumulated in 6/10 xenograft of either type (quadrants I and II). C) In vivomultispectral images shows accumulation of dQ-MG-754 in vital tumor regions of
A431/CCK2R (right arrow) and centralized localization of IR800 2-DG in A431/CCK2R and A431/WT xenografts (left arrow). Images were acquired with the Maestro. D) A431/
CCK2R tumors show dQ-MG-754 ﬂuorescence ex vivo (Maestro; ﬂuorescence displayed in grey) and in cryosections (Odyssey 800 nm channel; ﬂuorescence displayed in green)
and were positive for CCK2R expression in immunohistochemical staining (upper row). A431/WT tumors showed weak dQ-MG-754 ﬂuorescence ex vivo and in cryosections and
were negative for CCK2R expression in immunohistochemical staining (lower row). E) IR800 2-DG accumulation displayed two phenotypes, independently of CCK2R expression.
Either IR800 2-DG ﬂuorescence was strong in the central region of the xenograft and weak in the vital tumor margin (upper row) or IR800 2-DG showed overall weak ﬂuorescence
in the specimen (lower row). Both cases revealed comparable GLUT-1 staining.
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positive in xenografts that did not accumulate IR800 2-DG (Fig. 6E).
4. Discussion
Our data demonstrate that the CCK2R expressed on the surface
of tumor cells can be detected together with other contrast agents
addressing further tumor physiologies.
Our dQ-MG-754 probe showed a very high binding afﬁnity,
speciﬁcity and receptormediated internalization to a cytoplasmatic
location in a transfected cell model. Probe internalization also
conﬁrms that the receptor binding capability of the peptidewas not
impaired after coupling to the dye. Such effects are readily known
to occur when coupling a relatively large dye to a small peptide
molecule with limited binding sites involved in receptor binding
[19].
In vivo small animal imaging further conﬁrmed the suitability of
the dQ-MG-754 probe for optical imaging. Clear tumor identiﬁca-
tion of CCK2R transfected tumors and non-transfected colorectal
cancer xenografts was possible from at least 2e24 h after probe
application due to relatively high tumor to background ratios. High
TBRs were enabled by strong probe hydrophilicity, attained bycombining a minigastrin molecule containing six glutamines at the
N-terminus with the hemicyanine DY-754 with four negatively
charged sulfonate groups. Our results indicate that the pronounced
hydrophilicity leads to a shorter period of EPR based retention in
the tumor area, caused by a reduction of plasma protein binding
[32], leading to increase TBRs in comparison to the signaling of a
minigastrin probe coupled to the less hydrophilic DY-676 with only
two sulfonate groups [18]. Additionally, this less hydrophilic probe
presented intensely high ﬂuorescence in feces after hepatobiliary
elimination. dQ-MG-754 on the other hand, showed renal elimi-
nation and no unspeciﬁc signals in the gastrointestinal tract, which
is of particular importance for the prospective application in
endoscopic colorectal cancer screening.
The renal elimination of the dQ-MG-754 probe was accompa-
nied by strong kidney retention, although such retention of the
respective probe components was rather inconspicuous: the hy-
drophilic but uncharged DOTA-coupled dQ6-minigastrin peptide
sequence was shown to manifest in low kidney uptake [27] and in
our experiments the uptake of the DY-754 per se in the kidney was
negligible (data not shown). The increased kidney retention of the
probe is attributed to the combined inﬂuence of the negative
charges of the dye and the hydrophilicity of the peptide. This
S. Kossatz et al. / Biomaterials 34 (2013) 5172e5180 5179hypothesis is further supported by the fact that other negatively
charged minigastrins also display high kidney uptake [33].
In relation to the intended application, the large kidney uptake
of the probe will not impair the imaging process in intraoperative
and endoscopic imaging. In addition, kidney retention is unlikely to
damage kidney cells, since no ionizing radiation will be applied.
If we summarize our results related to the “dQ-MG-754”
CCK2R targeted probe, it becomes clear that it combines
numerous favorable properties to be considered for use in
endoscopic imaging. The low molecular weight, high target af-
ﬁnity, long speciﬁc tumor retention, high hydrophilicity and renal
elimination render the probe an excellent candidate to be used in
preclinical small animal imaging and for evaluation for intra-
operative and endoscopic imaging applications in the future. A
promising future application for the dQ-MG-754 probe is the
identiﬁcation of early adenomatous legions in colorectal cancer
screenings. We could basically show feasibility of this approach
by successful in vitro and in vivo imaging of colorectal cancer cells
physiologically expressing the CCK2R. The CCK2R has been shown
to be involved in tumorigenesis, e.g. vascularization and prolif-
eration of tumor cells in CRC, but is not expressed in the normal
colon [6,8,14]. Interestingly the divergence of reported CCK2R
prevalence in colorectal tumors [8,12,34,35], seems to be attrib-
uted, at least in part, to a gross underestimation of receptor
expression, as this receptor is rapidly translocated to an intra-
cellular location after ligand binding [36]. Moreover, our CCK2R
targeted probe goes beyond those which are currently available
for microendoscopy and ﬂuorescence endoscopy. Their spectral
properties are mainly allocated to the visible light spectrum (e.g.
FITC) where extensive tissue and feces autoﬂuorescence can
overlap with the target signal [37]. At wavelengths above 700 nm
signal to noise contrast is enhanced by profoundly reduced
autoﬂuorescence levels [38].
Beyond the detection of CCK2R via the dQ-MG-754 probe, a
multispectral approach is also feasible. Multispectral imaging is a
peculiarity of optical technologies allowing the in vivo detection of
more than onemolecular marker. The utilization of the probe IR800
2-DG, which targets elevated glycolysis and is the optical counter-
part of the clinically established 18F-FDG probe in nuclear medicine,
revealed a distinct intratumoral accumulation pattern. The ﬂuo-
rescence signals of the IR800 2-DG concentrated prominently in the
central region of tumors coinciding histologically with areas of
necrosis as a result of an EPR dependent accumulation. Obviously,
the incorporation of a dye molecule in the 2-deoxyglucose target-
ing moiety leads to speciﬁc opsonization processes with serum
proteins [39,40], which modiﬁes corresponding binding kinetics
after crossing the leaky tumor vasculature [24].
The fact that in vivo ﬂuorescence signals were indeed detected
in the vital tumor area after application of the IR800 2-DG probe
implies that speciﬁc binding to GLUT receptor presenting tumor
cells takes place. In this context, Kovar et al. [22] and Keereweer
et al. [23] showed that binding could be blocked by more than 50%
with excess GLUT-1 antibody or excess 2-deoxy-D-glucose in vitro.
Nevertheless, to our knowledge no in vivo blocking experiments
have been published to date.
From these investigations it can be concluded that signaling of
IR800 2-DG is related to both the selective binding to the GLUT-
receptors as was shown by competitive approaches but also the
result of the EPR effect. Hence, the IR800 2-DG probe additionally
provides valuable information related to probe accessibility and
perfusion of the tumor which allows us to exclude false negative
probe signaling. Additionally, the proposed selective accumulation
in necrotic tumor areas can provide valuable information on tumor
aggressiveness and therapy planning because necrotic tumors are
known to be correlated with poor prognosis [40].Our data also demonstrate the distinct effect of the dye
component used in the small molecule probes. For the CCK2R tar-
geted dQ-MG-754 probe this means that the dedicated selection of
the dye can favor pharmacokinetic and biodistribution features for
intraoperative and endoscopic imaging. In contrast, the presence of
a cyanine dye in GLUT targeted probes seems to shift receptor
speciﬁcity towards accumulation in necrotic areas as opposed to
uptake into vital GLUT-1 expressing cells in 18F-FDG imaging. This is
probably the reason for contradictory data in previous studies
[22,24].
Complementation of imaging of tumor speciﬁc surface receptors
with e.g. angiogenesis markers, glycolysis or other hallmarks of
cancer can be used to predict response to anti-cancer therapy.
Furthermore, analysis of tumor heterogeneity can also be a strong
predictor of therapy outcome [41].
5. Conclusion
We successfully performed multifactorial in vivo imaging based
on the detection of CCK2R overexpression in conjunction with
further tumor pathologies. We showed that the CCK2R targeted
dQ6-minigastrin based NIR optical probe “dQ-MG-754” applied in
this study was especially designed to unite speciﬁc high afﬁnity
binding with renal elimination and a favorable biodistribution.
Besides detecting GLUT-1 receptors, the ﬂuorescent 2-DG probe
also identiﬁed areas of necrosis.
We also demonstrated that the features of the respective NIR
optical probes cannot simply be extrapolated from their respective
radio-conjugated counterparts. Particularly for endoscopic appli-
cations, issues in relation to biodistribution and probe elimination
are of great importance beyond target afﬁnity.
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